Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Schafer

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Biochemical Pharmacology|January 20, 2012
Apremilast mechanism of action and application to psoriasis and psoriatic arthritisPeter Schafer
Expert Review of Anticancer Therapy|October 15, 2010
Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromesCarla Heise, Troy Carter, Peter Schafer, et al.
Maternal and Child Health Journal|December 22, 2025
Community-Led Solutions to Build Safer, More Equitable Places to Birth: The Baltimore Patients as Partners ProjectLashelle Stewart, Maxine Reed-Vance, Teneele Bruce, et al.
Drug Discovery Today|November 1, 2005
Keynote review: phosphodiesterase-4 as a therapeutic targetMiles D Houslay, Peter Schafer, Kam Y J Zhang
Therapeutic Advances in Musculoskeletal Disease|August 8, 2012
Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseasesGeorg Schett, Victor S Sloan, Randall M Stevens, et al.
Frontiers in Immunology|October 15, 2024
Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathwaysBrandon Johnson, Lihong Cheng, Jennifer Koenitzer, et al.
Maternal and Child Health Journal|February 14, 2007
Neighborhood mapping and evaluation: a methodology for participatory community health initiativesRobert E Aronson, Anne B Wallis, Patricia J O'Campo, et al.
Journal of Dermatological Science|December 3, 2019
Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL studyBruce Strober, Ali Alikhan, Benjamin Lockshin, et al.
European Journal of Drug Metabolism and Pharmacokinetics|July 14, 2005
Transport of thalidomide by the human intestinal caco-2 monolayersShufeng Zhou, Yan Li, Phillip Kestell, et al.
Cancer Immunology, Immunotherapy : CII|September 18, 2010
Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markersLei Wu, Anastasia Parton, Ling Lu, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Biochemical Pharmacology|January 20, 2012
Apremilast mechanism of action and application to psoriasis and psoriatic arthritisPeter Schafer
Expert Review of Anticancer Therapy|October 15, 2010
Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromesCarla Heise, Troy Carter, Peter Schafer, et al.
Maternal and Child Health Journal|December 22, 2025
Community-Led Solutions to Build Safer, More Equitable Places to Birth: The Baltimore Patients as Partners ProjectLashelle Stewart, Maxine Reed-Vance, Teneele Bruce, et al.
Drug Discovery Today|November 1, 2005
Keynote review: phosphodiesterase-4 as a therapeutic targetMiles D Houslay, Peter Schafer, Kam Y J Zhang
Therapeutic Advances in Musculoskeletal Disease|August 8, 2012
Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseasesGeorg Schett, Victor S Sloan, Randall M Stevens, et al.
Frontiers in Immunology|October 15, 2024
Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathwaysBrandon Johnson, Lihong Cheng, Jennifer Koenitzer, et al.
Maternal and Child Health Journal|February 14, 2007
Neighborhood mapping and evaluation: a methodology for participatory community health initiativesRobert E Aronson, Anne B Wallis, Patricia J O'Campo, et al.
Journal of Dermatological Science|December 3, 2019
Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL studyBruce Strober, Ali Alikhan, Benjamin Lockshin, et al.
European Journal of Drug Metabolism and Pharmacokinetics|July 14, 2005
Transport of thalidomide by the human intestinal caco-2 monolayersShufeng Zhou, Yan Li, Phillip Kestell, et al.
Cancer Immunology, Immunotherapy : CII|September 18, 2010
Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markersLei Wu, Anastasia Parton, Ling Lu, et al.
Pageof 6